NMN — Supplements
Direct NAD+ precursor with emerging evidence for age-related metabolic decline and cellular rejuvenation.
Overview
Nicotinamide mononucleotide (NMN) is a direct biosynthetic precursor to NAD+ via the enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT). NMN supplementation effectively raises NAD+ levels in human clinical trials, with landmark studies demonstrating improved muscle insulin sensitivity in prediabetic women (Science, 2021) and enhanced aerobic capacity in recreational runners. NMN is converted to NAD+ more rapidly than nicotinamide riboside and does not require conversion to NR as an intermediate. Multiple RCTs confirm safety and bioavailability at doses up to 1,200 mg/day.
Indications
- NAD+ repletion and longevity support
- Insulin sensitivity and metabolic health
- Exercise capacity enhancement
- Age-related cellular decline mitigation
Mechanism of Action
NMN is converted to NAD+ by nicotinamide mononucleotide adenylyltransferase in the salvage pathway
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| NMN | 500 mg | Once daily (morning) | Take in the AM for circadian alignment; sublingual forms may improve absorption |
Evidence Grade
GRADE B
Safety & Contraindications
- Well tolerated in clinical trials up to 1,200 mg/day for 60 days
- No significant adverse effects reported in human RCTs to date
- Long-term safety data (>1 year) is still limited
- Purity and stability vary between manufacturers; choose third-party tested products